Zeo ScientifiX, Inc.

Zeo ScientifiX announced it will host a live virtual educational webinar for healthcare professionals on July 22, 2026. Titled "One Year Later, Three States Stronger: The Southeast Regen Revolution," the webinar will discuss lessons from Florida's stem cell law and its implications for physicians in other states like Tennessee and Georgia as regenerative medicine expands. The event aims to advance physician education and foster evidence-based discussions on responsible innovation, featuring a panel of scientific, medical, and regulatory experts.

Zeo ScientifiX announced that it donated products to support a humanitarian medical mission in Cusco, Peru. Dr. Constantino Mendieta, a member of ZEO's Medical Advisory Board, participated in the 10-day mission, providing specialized reconstructive care to approximately 38 child patients recovering from severe burn injuries using the donated products. The initiative reflects the company's commitment to physician-led care and expanding access to advanced therapeutic options.

Zeo ScientifiX, Inc. (ZEOX) filed its Form 10-Q for the period ending April 30, 2026. The company reported a significant increase in revenues to $4,027,000 for the first six months of the fiscal year, up from $2,239,000 in the prior year. This revenue growth contributed to a reduced net loss of $997,000, an improvement from $2,634,000 in the same period last year. The company also recognized a $390,000 gain from the sale of its Exotropin interests. Despite these improvements, the company continues to face challenges related to its going concern status, with substantial doubt expressed about its ability to continue operations without additional funding.

Zeo ScientifiX, Inc. awarded a total of 3,830,000 stock options under its 2021 Incentive Stock Plan on June 10, 2026. These options were granted to Greyt Ventures LLC, CEO Ian Bothwell, CMO George Shapiro, and non-executive director Chuck Bretz. The awards include both immediately vested options and performance-based incentive options, all with an exercise price of $1.67 per share.

Zeo ScientifiX, Inc. announced the expansion of its Medical Advisory Board with the addition of nine highly-recognized physicians and scientific innovators. This move strengthens the company's scientific leadership across key disciplines in regenerative and longevity medicine, including orthopedics, oncology, and pain management. The expanded board will focus on advancing scientific rigor, clinical standards, and physician education as access to regenerative medicine grows in the United States.

Zeo ScientifiX, Inc. announced the formal launch of its Physician-Led Patient Masterclass program. This initiative is designed to empower physicians to educate their patient populations on regenerative medicine, addressing a significant demand for information. The program formalizes a model that emerged organically from a physician-organized event and follows the company's training of over 600 physicians in regenerative therapies across the Southeast.

ZEO ScientifiX announced that its unaudited monthly sales surpassed $1 million in April 2026, marking a historic first for the company. Management considers this a significant inflection point, attributing the growth to a successful physician-first commercial strategy. Key drivers include a newly implemented dedicated internal sales force and physician education initiatives, with plans to further expand the sales team.

ZEO ScientifiX, Inc. announced a significant milestone, having successfully trained over 500 clinicians through its monthly Masterclass series focused on regenerative biologics treatments. The company's educational program, held at Nova Southeastern University, has become a vital resource for physicians navigating the evolving regulatory and scientific landscape of regenerative medicine. This achievement highlights ZEO's commitment to clinical education and its growing influence in the field.

Zeo ScientifiX, Inc. (ZEOX) has entered into an exclusive scientific and biologics strategic collaboration with Regen Therapy, positioning ZEO as the core supplier of advanced biologic therapeutics for Regen's next-generation regenerative offerings. This partnership is integral to Regen Therapy's broader initiative with Stealth Health, aiming to deliver specialized telemedicine services and longevity programs to an extensive network of 3,000 clinics. The collaboration leverages Regen Therapy's 24,000-practitioner network to establish a fully integrated care ecosystem, significantly expanding ZEO's market reach and strategic importance in the regenerative medicine space.

Zeo ScientifiX (ZEOX) announced its selection as a Qualified Team advancing to the Semi-Finals of the XPRIZE Healthspan competition. This selection could enhance the company's visibility and credibility in the health technology sector, potentially attracting investment and partnerships.